Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial
Caryn M Upton, Rob C van Wijk, Laurynas Mockeliunas, Ulrika S H Simonsson, Kirsten McHarry, Gerben van den Hoogen, Chantal Muller, Arné von Delft, Helene-Mari van der Westhuizen, Reinout van Crevel, Gerhard Walzl, Pedro M Baptista, Jonathan Peter, Andreas H Diacon, BCG CORONA Consortium, Caryn M Upton, Rob C van Wijk, Laurynas Mockeliunas, Ulrika S H Simonsson, Kirsten McHarry, Gerben van den Hoogen, Chantal Muller, Arné von Delft, Helene-Mari van der Westhuizen, Reinout van Crevel, Gerhard Walzl, Pedro M Baptista, Jonathan Peter, Andreas H Diacon, BCG CORONA Consortium
Abstract
Background: BCG vaccination prevents severe childhood tuberculosis (TB) and was introduced in South Africa in the 1950s. It is hypothesised that BCG trains the innate immune system by inducing epigenetic and functional reprogramming, thus providing non-specific protection from respiratory tract infections. We evaluated BCG for reduction of morbidity and mortality due to COVID-19 in healthcare workers in South Africa.
Methods: This randomised, double-blind, placebo-controlled trial recruited healthcare workers at three facilities in the Western Cape, South Africa, unless unwell, pregnant, breastfeeding, immunocompromised, hypersensitivity to BCG, or undergoing experimental COVID-19 treatment. Participants received BCG or saline intradermally (1:1) and were contacted once every 4 weeks for 1 year. COVID-19 testing was guided by symptoms. Hospitalisation, COVID-19, and respiratory tract infections were assessed with Cox proportional hazard modelling and time-to-event analyses, and event severity with post hoc Markovian analysis. This study is registered with ClinicalTrials.gov, NCT04379336.
Findings: Between May 4 and Oct 23, 2020, we enrolled 1000 healthcare workers with a median age of 39 years (IQR 30-49), 70·4% were female, 16·5% nurses, 14·4% medical doctors, 48·5% had latent TB, and 15·3% had evidence of prior SARS-CoV-2 exposure. Hospitalisation due to COVID-19 occurred in 15 participants (1·5%); ten (66·7%) in the BCG group and five (33·3%) in the placebo group, hazard ratio (HR) 2·0 (95% CI 0·69-5·9, p = 0·20), indicating no statistically significant protection. Similarly, BCG had no statistically significant effect on COVID-19 (p = 0·63, HR = 1·08, 95% CI 0·82-1·42). Two participants (0·2%) died from COVID-19 and two (0·2%) from other reasons, all in the placebo group.
Interpretation: BCG did not protect healthcare workers from SARS-CoV-2 infection or related severe COVID-19 disease and hospitalisation.
Funding: Funding provided by EDCTP, grant number RIA2020EF-2968. Additional funding provided by private donors including: Mediclinic, Calavera Capital (Pty) Ltd, Thys Du Toit, Louis Stassen, The Ryan Foundation, and Dream World Investments 401 (Pty) Ltd. The computations were enabled by resources in project SNIC 2020-5-524 provided by the Swedish National Infrastructure for Computing (SNIC) at UPPMAX, partially funded by the Swedish Research Council through grant agreement No. 2018-05,973.
Keywords: BCG; COVID-19; Pandemic; Respiratory tract infection; Trained immunity; Tuberculosis; Vaccine.
Conflict of interest statement
We declare no competing interests.
© 2022 The Author(s).
Figures
References
- National Institute of Communicable Diseases. Daily hospital surveillance (DATCOV) report. 2022; . Accessed 3 May 2022
- Singh A.K., Netea M.G., Bishai W.R. BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases. J Clin Invest. 2021;131:1–11.
- Trunz B.B., Fine P., Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367:1173–1180.
- Van der Walt M, Moyo S. The first national TB prevalence survey, South Africa; 2018.
- Hesseling A.C., Caldwell J., Cotton M.F., et al. BCG vaccination in South African HIV-exposed infants - risks and benefits. S Afr Med J. 2009;99:88–93.
- Miller A., Reandelar M.J., Fasciglione K., Roumenova V., Li Y., Otazu G.H. Correlation between universal BCG vaccination policy and reduced mortality for COVID-19. medRxiv. 2020:1–15.
- Bagheri N., Montazeri H. On BCG vaccine protection from COVID-19: a review. SN Compr Clin Med. 2021;3:1261–1271.
- Giamarellos-Bourboulis E.J., Tsilika M., Moorlag S., et al. Activate: randomized clinical trial of BCG vaccination against infection in the elderly. Cell. 2020;183:315–323.e9.
- Benn C.S., Martins C.L., Andersen A., Fisker A.B., Whittle H.C., Aaby P. Measles vaccination in presence of measles antibody may enhance child survival. Front Pediatr. 2020;8:1–6.
- Sørup S., Stensballe L.G., Krause T.G., Aaby P., Benn C.S., Ravn H. Oral polio vaccination and hospital admissions with non-polio infections in Denmark: nationwide retrospective cohort study. Open Forum Infect Dis. 2016;3:1–9.
- Aaby P., Benn C.S. Developing the concept of beneficial non-specific effect of live vaccines with epidemiological studies. Clin Microbiol Infect. 2019;25:1459–1467.
- Berg M.K., Yu Q., Salvador C.E., Melani I., Kitayama S. Mandated bacillus calmette-guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19. Sci Adv. 2020;6:1–9.
- WHO R&D blueprint: novel coronavirus: COVID-19 therapeutic trial synopsis, World Health Organization, 2020.
- Moorlag S.J.C.F.M., Arts R.J.W., van Crevel R., Netea M.G. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019;25:1473–1478.
- University Medical Center Utrecht. Tuberculosis vaccine does not protect vulnerable elderly people against COVID-19. 2021. . Accessed 3 May 2021.
- Tsilika M., Taks E., Dolianitis K., et al. ACTIVATE-2: a double-blind randomized trial of BCG vaccination against COVID19 in individuals at risk. medRxiv. 2021:1–31.
- Barry C.E., Boshoff H.I., Dartois V., et al. The spectrum of latent tuberculosis: rethinking the goals of prophylaxis. Nat Rev Microbiol. 2009;7:845–855.
- Marakalala M.J., Martinez F.O., Plüddemann A., Gordon S. Macrophage heterogeneity in the immunopathogenesis of tuberculosis. Front Microbiol. 2018;9:1–15.
- Mpande C.A.M., Rozot V., Mosito B., et al. Immune profiling of mycobacterium tuberculosis-specific T cells in recent and remote infection. EBioMed. 2021;64 doi: 10.1016/j.ebiom.2021.103233.
- Khan N., Downey J., Sanz J., et al. M. tuberculosis reprograms hematopoietic stem cells to limit myelopoiesis and impair trained immunity. Cell. 2020;183:752–770.e22.
- Andersen P., Doherty T. The success and failure of BCG — implications for a novel tuberculosis vaccine. Nat Rev Microbiol. 2005;3:656–662.
- Nemes E., Geldenhuys H., Rozot V., et al. Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med. 2018;379:138–149.
- Wardhana, Datau E.A., Sultana A., Mandang V.V, Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indones. 2011;43:185–190.
- Goronzy J.J., Weyand C.M. Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 2013;14:428–436.
- Hilligan K.L., Namasivayam S., Clancy C.S., et al. Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge. J Exp Med. 2021;219:1–14.
- Weekly respiratory pathogens surveillance report. Natl Inst Commun Dis. 2021
- Miettinen O.S. Survival analysis: up from Kaplan-Meier-greenwood. Eur J Epidemiol. 2008;23:585–592.
Source: PubMed